Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
DexCom Inc.
DXCMHealthcareGenerated Jul 5, 2026, 08:13 PM UTC
DXCM (DexCom Inc.) analytical snapshot. Return on equity 25.40%, ROA 8.35%, ROIC 28.04%. Net income up ▲ +58.7% YoY. Debt/equity 0.00, current ratio 1.95, net debt -$1.12B. Market cap $27.49B at $71.25 per share. Trailing P/E 54.81, P/S 236.60, P/B 9.30. EV/Operating income ≈ 44.13 (EV $26.38B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score -7 (data confidence 84%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFundamentals
Return on equity 25.40%, ROA 8.35%, ROIC 28.04%. Net income up ▲ +58.7% YoY. Debt/equity 0.00, current ratio 1.95, net debt -$1.12B.
- Return on equity 25.40%, ROA 8.35%, ROIC 28.04%.
- Net income up ▲ +58.7% YoY.
- Debt/equity 0.00, current ratio 1.95, net debt -$1.12B.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | $72.8M | — | 242.17 | -29.53 | -30.77 | $7.4M | — |
| 2017 | $116.2M | +59.6% | 239.59 | -49.14 | -49.57 | $15.7M | — |
| 2018 | — | — | — | — | — | $500.0K | — |
| 2019 | — | — | — | — | — | $26.0M | — |
| 2020 | — | — | — | — | — | $56.1M | — |
| 2021 | — | — | — | — | — | $134.5M | 15.24 |
| 2022 | — | — | — | — | — | $276.6M | 62.28 |
| 2023 | — | — | — | — | — | $53.3M | 13.98 |
| 2024 | — | — | — | — | — | $304.7M | 16.71 |
| 2025 | — | — | — | — | — | $511.9M | 25.40 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Sep 30, 2017 | $184.6M | -54.1% | — | -22.10% |
| Mar 31, 2018 | $184.4M | +29.6% | -0.1% | -13.12% |
| Jun 30, 2018 | $426.9M | +36.4% | +131.5% | 1.41% |
| Jun 30, 2018 | $242.5M | -22.5% | -43.2% | 2.47% |
| Sep 30, 2018 | $693.6M | +39.4% | +186.0% | 7.58% |
| Sep 30, 2018 | $266.7M | -46.4% | -61.5% | 19.72% |
Filings & Ownership
Latest annual report (10-K) filed Feb 12, 2026. Latest quarterly report (10-Q) filed Apr 30, 2026. 13 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 12, 2026.
- Latest quarterly report (10-Q) filed Apr 30, 2026.
- 13 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference DexCom Inc.; broad institutional reporting.
- Recent filers include PURA VIDA INVESTMENTS, LLC, Rothschild Capital Partners, LLC, WS MANAGEMENT LLLP.
| Filer | Form | Filed |
|---|---|---|
| PURA VIDA INVESTMENTS, LLC | 13F-HR | Nov 14, 2017 |
| Rothschild Capital Partners, LLC | 13F-HR | May 4, 2016 |
| WS MANAGEMENT LLLP | 13F-HR | May 11, 2023 |
| WS MANAGEMENT LLLP | 13F-HR | Nov 13, 2023 |
| Atika Capital Management LLC | 13F-HR | Aug 14, 2018 |
| Date | Form | Description |
|---|---|---|
| May 28, 2026 | 8-K | 8-K |
| May 15, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Mar 2, 2026 | 8-K | 8-K |
| Feb 26, 2026 | 8-K | 8-K |
| Feb 12, 2026 | 8-K | 8-K |
| Jan 12, 2026 | 8-K | 8-K |
| Dec 22, 2025 | 8-K | 8-K |
SEC Filing Deep-Analysis
1 risk signal(s), 1 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- Gross margin compression: Gross margin contracted +616.9%pp (from 2586.7% to 1969.8%). This may reflect input cost inflation, pricing pressure, or product mix shift toward lower-margin segments.
- Operating cash flow exceeds net income: OCF is 1.38x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- R&D intensity declining: R&D as % of revenue fell from 665.1% to 435.3%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
- Endogenous analysis: 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 4 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $72.8M | $116.2M | $43.4M | +59.6% |
| Gross profit | $1.88B | $2.29B | $405.8M | +21.5% |
| Operating income | $391.2M | $597.7M | $206.5M | +52.8% |
| Net income | $341.2M | $541.5M | $200.3M | +58.7% |
| Operating cash flow | $669.5M | $748.5M | $79.0M | +11.8% |
| Capex | $364.8M | $236.6M | $-128.2M | -35.1% |
| Total assets | $6.26B | $6.48B | $220.0M | +3.5% |
| Total liabilities | $4.20B | $4.38B | $186.0M | +4.4% |
| Long-term debt | $6.8M | $4.6M | $-2.2M | -32.4% |
| Cash & equivalents | $642.3M | $566.3M | $-76.0M | -11.8% |
| Stockholders equity | $2.04B | $2.13B | $89.7M | +4.4% |
| Inventory | $559.6M | $542.6M | $-17.0M | -3.0% |
| Accounts receivable | $973.9M | $1.01B | $31.8M | +3.3% |
| R&D expense | $484.2M | $505.8M | $21.6M | +4.5% |
| SG&A expense | $1.01B | $1.19B | $177.7M | +17.6% |
| Interest expense | $17.7M | $18.8M | $1.1M | +6.2% |
| Type | Concepts |
|---|---|
| Added | AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation, EquitySecuritiesWithoutReadilyDeterminableFairValueAmount, EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount, PaymentsRelatedToTaxWithholdingForShareBasedCompensation |
| Removed | AccountsReceivableGross, AccountsReceivableNet, AccruedIncomeTaxesNoncurrent, AdvertisingExpense, AllowanceForDoubtfulAccountsReceivable, AmortizationOfIntangibleAssets, AvailableForSaleDebtSecuritiesAmortizedCostBasis, AvailableForSaleSecuritiesDebtSecurities, AvailableForSaleSecuritiesDebtSecuritiesCurrent, AvailableForSaleSecuritiesDebtSecuritiesNoncurrent |
Unlock the rest
- ProValuationMarket cap $27.49B at $71.25 per share.
- ProPrice & TechnicalsPrice $71.25 — uptrend (above 200-DMA); 1-month momentum negative.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Moderate.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -7
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. DexCom Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewReturn on equity **25.40%**, ROA 8.35%, ROIC 28.04%..
Peer comparison
Defensive groupHow DXCM stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM● you | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |